Investor Relations
Investor Relations
CORPORATE PROFILE
We are a clinical late-stage pharmaceutical company focused on the development and commercialization of first-in-class pharmaceutical therapies for the treatment of ocular blinding diseases. Our product candidates are based on dazdotuftide, a New Chemical Entity, which is a potent local immunomodulatory agent. Dazdotuftide is being developed as an eye drop formulation, TRS01, to treat the signs and symptoms of active uveitis in patients with uveitic glaucoma. The company announced the results of the first Phase 3 clinical trial, and based on the safety and potency of the TRS01 and a positive Type C meeting with the FDA, plans to initiate a second Phase 3 trial. The company is also developing TRS02, a slow-release formulation of the same compound, to be administered as intravitreal injections for the treatment of various back-of-the-eye retinal blinding diseases.
NEWS
January 16, 2024
Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution for the Treatment of Non-infectious Uveitis including Uveitic Glaucoma
November 13, 2023
Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis
August 23, 2023
Tarsier Pharma Announces Results from a Phase 3 Clinical trial in Subjects with Noninfectious Anterior Uveitis Including Subjects with Uveitic Glaucoma
June 12, 2023
Tarsier Pharma Announces Publication of Review Article on Suppressing Inflammation for Treating Retinal Blinding Ocular Diseases, Highlighting dazdotuftide (TRS) as a Promising Therapeutic Candidate
16 August, 2022
Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation
26 June, 2022
Tarsier® Pharma receives certificate of registration for trademark Tarsier® in the US & other territories
21 March, 2022
Bridging the Gender Gap in Scientific Innovation: Tarsier’s CEO, Dr. Daphne Haim-Langford, is interviewed in Oppenheimer’s “Let’s Talk Future™” podcast about women in scientific innovation
March 3, 2022
Dr. Daphne Haim-Langford will participate as keynote speaker at the Israeli Society for Vision and Eye Research (ISVER) Annual Meeting
March 01, 2022
Tarsier Pharma Adds Ocular Immunology Experts to Scientific Advisory Board
Feb 08, 2022
Dr. Daphne Haim-Langford presents Tarsier’s progress to the European Parliament
December 2, 2021
Tarsier Pharma Announces two presentations at the International Ocular Inflammation Society (IOIS) 2021 Congress
30 November 2021
Tarsier’s CEO and Founder, Dr. Daphne Haim Langford, wins the 2021 EU Prize for Women Innovators
November 8, 2021
TRS01 Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual meeting
September 22, 2021
First Patient Randomized in TRS4VISION Phase-III Clinical Trial in Patients with Active Non-Infectious Anterior Uveitis Including Patients with Uveitic Glaucoma
July 28, 2021
Tarsier Pharma, in Collaboration with Uveitis Experts, Published a Research Article about a New Grading Image Scale for Assessing Uveitis
April 26, 2021
Tarsier Pharma Completes Successful Pre-IND Meeting with the FDA for its TRS02 Program of Back-of-the-Eye Blinding Indications
17 October, 2020
Tarsier Pharma’s Positive End-Of-Phase 2 Meeting With The U.S. FDA Sets Stage For TRS01 Phase III Program In Uveitis
October 5, 2020
Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitis
June 22, 2020
Tarsius Pharma Completes Patient Enrollment In Clinical Trial Of TRS01 In Patients With Non-Infectious Uveitis
Feb. 25, 2020
Dosing of first patient in Tarsius 2020 Phase I/IIa Clinical Study of TRS01
Feb. 04, 2020
Dosing Of First Patient In GADOT 20/20 Trial, A Phase I/IIa Study Of TRS01 In Patients With Non-Infectious Anterior Uveitis
Nov. 19, 2019
Tarsius Pharma Announces Granting Of Orphan Drug Designation For TRS By The European Medicines Agency
Oct. 6, 2019
BioLight’s New Investment In Tarsius Pharma Ltd. That Develops A Novel Platform For The Treatment Of Blinding Ocular Diseases
Sept. 16, 2019
Tarsius Pharma Awarded €2.4 Million EU Grant To Support First-In-Human Clinical Trial For TRS01
EVENTS
March 22-24, 2024
Tarsier Pharma Announces Participation at the Sonoma Eye 2024 Symposium
January 10, 2024
Tarsier Pharma Announces Presentation at the 27th Annual AUS Winter Symposium
November 30, 2023
Tarsier Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
The Session Recording Will Be Available By The End Of 2023
Challenges in Uveitic Glaucoma Treatment: ARVO Special Interest Group
November 5, 2023
Tarsier Pharma Will Participate at the American Uveitis Society Fall Meeting at the AAO
October 07, 2023
TRS4Vision data to be presented at the Uveitis Webinar 30: Glaucoma in uveitis – IUSG (International uveitis study group)
October 04, 2023
Tarsier Pharma Will Present At the Ophthalmology Futures Retina Forums 2023
September 26-28, 2023
Tarsier Pharma Will Participate at the Cantor annual Global Healthcare Conference
September 7, 2023
Tarsier Pharma Will Present At The Ophthalmology Futures European Forum 2023
September 6-9, 2023
Tarsier Pharma Will Participate at the 17th International Ocular Inflammation Society (IOIS) Congress
April 17-20, 2023
Tarsier Pharma Will Participate at the 22nd Annual Needham Virtual Healthcare Conference
December 8, 2022
Tarsier at the upcoming Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
30 October – 1 November, 2022
Tarsier’s CEO, Dr. Daphne Haim-Langford, will present at the Hadassah Eye & Vision Innovation Forum
15 September, 2022
Tarsier Pharma Will Present At The Ophthalmology Futures European Forum
September 12-14, 2022
Tarsier Pharma Will Participate At The H.C. Wainwright 24th Annual Global Investment Conference
August 25-27, 2022
Tarsier Pharma Will Participate at the 10th International Symposium on Uveitis
17 August, 2022
Tarsier Pharma announces participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
08 June, 2022
Virtual Panel Of Cantor And Fitzgerald Will Discuss Market Opportunities In Ophthalmic Indications, Hosting Tarsier Pharma
April 11-14, 2022
Tarsier Pharma Will Participate at the 21st Annual Needham Virtual Healthcare Conference
March 15-17, 2022
Tarsier Pharma Will Participate At The Oppenheimer 32nd Virtual Annual Healthcare Conference
February 27-March 2, 2022
TRS01 potential presented at the American-European-Congress-of-Ophthalmic-Surgery by Dr. Raizman
January 10-13, 2022
Tarsier Pharma Will Participate At The H.C. Wainwright Bioconnect Conference
November 15, 2021
Tarsier Pharma Will Participate At The H.C. Wainwright 7th Annual Israel Virtual Conference
19-20 October, 2021
Tarsier Pharma Will Participate At The Needham Virtual Biotech Private Company 1×1 Forum
October 07, 2021
Tarsier Pharma Will Present At The Ophthalmology Futures European Forum
September 13-15, 2021
Tarsier Pharma Will Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
September 9-10, 2021
Tarsier Pharma Will Participate at the 2021 Wells Fargo Virtual Healthcare Conference
August 17, 2021
Tarsier Pharma Will Participate at the H.C. Wainwright Ophthalmology
Virtual Conference
21 May, 2021
Tarsier Pharma Will Participate In The Oppenheimer Rare & Orphan Disease Summit
12-15 April, 2021
Tarsier Pharma Will Present in the 20th Annual Needham Virtual Healthcare Conference
08 April, 2021
Tarsier Pharma Will Present in the Anterior Innovation Showcase of the Ophthalmology Innovation Summit (OIS)
16-18 March, 2021
Tarsier Pharma Will Participate in the Oppenheimer 31st Virtual Annual Healthcare Conference
19 February, 2021
Virtual panel of Cantor and Fitzgerald will discuss market opportunities in ophthalmic indications, hosting Tarsier Pharma
6-13 January, 2021
Tarsier Pharma’s to Participate at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021
12 December, 2020
Tarsius Pharma will present at the 4th Annual Sonoma Eye Conference results of its Phase I/II trial of TRS01 targeting Uveitis
30 November, 2020
Tarsius Pharma will Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 13-16, 2019
Tarsius’ Founder & CEO Will Present As Invited Speaker @ The 15th International Ocular Inflammation Society (IOIS) 2019
